Dr. Steven Lawrence Rosinski, MD, PhD

Dr. Rosinski practices at Phoenix Cancer and Blood Disorder Treatment Institute in Bullhead City, Arizona.

Dr. Rosinski's NPI, 1073621819, was assigned on August 29, 2006. Dr. Rosinski graduated from University of Colorado School of Medicine, Denver in 2005. Dr. Rosinski holds Washington license MD 60001467.

Dr. Rosinski's primary practice is Phoenix Cancer and Blood Disorder Treatment Institute, at 967 E Hancock Rd, Bullhead City, AZ 86442 in Mohave County. The practice phone is (928) 224-0064.

Dr. Rosinski's primary practice is Phoenix Cancer and Blood Disorder Treatment Institute in Bullhead City, Arizona. Dr. Rosinski is also affiliated with Western Arizona Regional Medical Center. The medical group on file is Phoenix Cancer Institute. Dmand AI also links Dr. Rosinski to 4 more hospitals and 1 group practice or clinic, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosinski practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Rosinski's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Rosinski is board certified in hematology by the American Board of Internal Medicine. Dr. Rosinski is licensed in Washington.

CMS data shows 74,633 Medicare services from Dr. Rosinski across 41 procedure codes in 2024, for 625 Medicare patients. Medicare paid $1,545,164 for them. Every service was in an office.

CMS counts 625 Medicare patients who saw Dr. Rosinski in 2024. The largest group is 65 to 74, with 290 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 11% are also on Medicaid. Their average risk score is 1.81, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosinski's median patient age at 72, with 48% women.

In 2024, Dr. Rosinski wrote 2,519 Medicare Part D claims for 434 patients. 89% of them were for generic drugs. CMS names the drug for 2,199 of them, across 58 drugs with 11 or more claims each, at $2,330,886 in total drug cost. In 2023, CMS named 2,095 claims across 56 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 29 out of 100 for Dr. Rosinski for performance year 2024, reported individually. Dr. Rosinski accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosinski as offering telehealth.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 8 papers to Dr. Rosinski, published from 2016 to 2019. 2016 was the busiest year, with 3. The most frequent topics are Dogs, Graft vs Host Disease and Bone Marrow Transplantation. Dr. Rosinski has published most often in Biol Blood Marrow Transplant. Dr. Rosinski's most frequent co-authors are Boglarka Gyurkocza, MD, Robert M. Rakita, MD and Andrew R. Rezvani, MD.

CMS Open Payments shows 770 general payments to Dr. Rosinski from 80 drug and device companies from 2017 to 2025. Food and beverage make up the largest share, 71% of the total. Novartis Pharmaceuticals Corporation paid the most, $5,119.

Dr. Rosinski graduated from University of Colorado School of Medicine, Denver in 2005.